Utreloxastat
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- Utreloxastat
- Molecular weight
- 276.42
- Structure (SMILES)
- CCCCCCCCCC1=C(C)C(=O)C(C)=C(C)C1=O
- ptc 857
- PTC-857
- ptc857
- Ptc857
- PTC857
- utreloxastat
- Utreloxastat
- utreloxastat [INN]
- UTRELOXASTAT [USAN]
- utreloxastat inn
- utreloxastat usan
- CAS registry numbers
- 1213269-96-5
- ChEMBL ID
- CHEMBL5314565
- InChIKey
- IJWAQTHZBDBIID-UHFFFAOYSA-N
- PubChem compound IDs
- 46174641
- FDA ingredient codes (UNII)
- WW8KZK2PZT
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- utreloxastat
- Type
- Synthetic organic
- Drug name stem
- -stat
Investigated indications
- Condition
- Nervous System Diseases
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000618
- Subject identifier
- D009422
- Condition identifier
- EFO_0000618
- Condition identifier
- MONDO_0004976
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005071
- Hydrogen bond acceptors
- 2
- Hydrogen bond donors
- 0
- Polar surface area
- 34.14
- Calculated partition coefficient (ALogP)
- 4.93
- Calculated partition coefficient (XLogP)
- 5.8
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 8
- Heavy atoms
- 20
- Molecular formula
- C18H28O2
- Monoisotopic mass
- 276.208930132
- Natural product
- No
Related records
Trials (1)
In development for (2)
- Amyotrophic lateral sclerosis Phase 2
- Nervous system disorder Phase 1